PIONEER 6 lead investigator Mansoor Husain discusses the results of the trial, and how oral and injectable semaglutide compare and can be used in the clinic (4:40).
More on this topic
- News story | Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6
- News story | Favourable cardiovascular safety profile for semaglutide
- Quick guide | Round-up of the GLP-1 receptor agonist CV outcome trials
- News story | PIONEER trials test oral semaglutide in moderate renal impairment, flexible dosing
- News story | PIONEER 2, PIONEER 4 show benefits of oral semaglutide in type 2 diabetes
- News story | PIONEER 3: Oral semaglutide proves worth against sitagliptin